IDEXX Laboratories, Inc. (IDXX)
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago.
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock?
IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities.
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Meet the Little-Known S&P 500 Stock That Has Rocketed 10,230% Higher Since 2000
Healthcare diagnostics equipment manufacturer, Idexx Laboratories (IDXX -1.54%), is the global leader in pet care.
Should You Retain IDEXX Stock in Your Portfolio for Now?
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
IDEXX Laboratories: Cancer Dx Launch In March 2025; Upgrading To 'Buy'
Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive significant growth and new revenue streams. IDEXX's share repurchase program is robust, with $837 million repurchased in FY24 and a plan for $1.5 billion in FY25.
